Uterine Cervical Incompetence Clinical Trial
Official title:
Randomised Trial of Cervical Cerclage With and Without Occlusion for the Prevention of Preterm Birth in Women Suspected for Cervical Insufficiency
Verified date | November 2012 |
Source | Hvidovre University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | Denmark: Ethics Committee |
Study type | Interventional |
The aim of this study was to evaluate the effect of cervical occlusion versus no cervical occlusion in women with cervical cerclages.
Status | Terminated |
Enrollment | 309 |
Est. completion date | August 2011 |
Est. primary completion date | August 2011 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - The physician in charge considered that a cerclage was indicated. - Gestational age between 12 and 27 completed weeks. - Previous late mid-trimester miscarriage, or spontaneous preterm labour and delivery before 28 weeks with or without previous cerclages. - Previous cerclage because of short cervix. - Confirmed gestational age defined as gestational age estimated by ultrasound at less than or equal to 22+0 weeks, and/or certain last menstrual period. - Vaginal infection treated before cerclage. - Ability to read and understand the relevant national language. - Consent obtained in accordance with specifications of the local research ethics committee. - 18 years or more of age and legally competent. Exclusion Criteria: - Demonstrated cervical infection. - Obstetrical complications in the current pregnancy. - Multiple pregnancies. - History of a significant abruptio placenta in a previous pregnancy. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Denmark | Department of Obstetrics and Gynecology, Hvidovre University Hospital, Denmark | Hvidovre | Zealand |
Lead Sponsor | Collaborator |
---|---|
Niels Jørgen Secher |
Australia, Denmark, India, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Days of admission to the neonatal intensive care unit | Neonates will be followed for the duration of stay in the neonatal intensive care unit, an expected average of 28 days with a minimum of 0 days up to a maximum of 98 days. | No | |
Primary | Take-home baby rate | Take-home baby rate was defined as the proportion of living babies discharged from the hospital of all singleton pregnancies. | Neonates will be followed for the duration of stay in the neonatal intensive care unit, an expected average of 28 days with a minimum of 0 days up to a maximum of 98 days. | No |
Secondary | Gestational age at birth | Evaluated as a continuous variable and as a dichotomous variable (<34+0 weeks gestation) | At birth | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02098382 -
Dilapan-S Osmotic Dilator in Pre-induction of Labor
|
N/A | |
Recruiting |
NCT05132829 -
Azithromycin to Improve Latency in Exam Indicated Cerclage Control Trial
|
Phase 4 |